AIM ImmunoTech (AIM) Competitors $8.79 -0.36 (-3.98%) Closing price 07/15/2025 03:57 PM EasternExtended Trading$8.45 -0.34 (-3.82%) As of 07/15/2025 06:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock AIM vs. SCYX, ENLV, NRSN, COEP, TPST, PASG, TENX, CARA, LSTA, and CVKDShould you be buying AIM ImmunoTech stock or one of its competitors? The main competitors of AIM ImmunoTech include SCYNEXIS (SCYX), Enlivex Therapeutics (ENLV), NeuroSense Therapeutics (NRSN), Coeptis Therapeutics (COEP), Tempest Therapeutics (TPST), Passage Bio (PASG), Tenax Therapeutics (TENX), Cara Therapeutics (CARA), Lisata Therapeutics (LSTA), and Cadrenal Therapeutics (CVKD). These companies are all part of the "pharmaceutical products" industry. AIM ImmunoTech vs. Its Competitors SCYNEXIS Enlivex Therapeutics NeuroSense Therapeutics Coeptis Therapeutics Tempest Therapeutics Passage Bio Tenax Therapeutics Cara Therapeutics Lisata Therapeutics Cadrenal Therapeutics SCYNEXIS (NASDAQ:SCYX) and AIM ImmunoTech (NYSE:AIM) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, media sentiment, institutional ownership and valuation. Does the media prefer SCYX or AIM? In the previous week, SCYNEXIS had 1 more articles in the media than AIM ImmunoTech. MarketBeat recorded 1 mentions for SCYNEXIS and 0 mentions for AIM ImmunoTech. SCYNEXIS's average media sentiment score of 1.87 beat AIM ImmunoTech's score of 0.00 indicating that SCYNEXIS is being referred to more favorably in the media. Company Overall Sentiment SCYNEXIS Very Positive AIM ImmunoTech Neutral Which has more risk & volatility, SCYX or AIM? SCYNEXIS has a beta of 1.57, suggesting that its stock price is 57% more volatile than the S&P 500. Comparatively, AIM ImmunoTech has a beta of 0.98, suggesting that its stock price is 2% less volatile than the S&P 500. Is SCYX or AIM more profitable? SCYNEXIS has a net margin of -1,030.04% compared to AIM ImmunoTech's net margin of -12,594.21%. SCYNEXIS's return on equity of -53.47% beat AIM ImmunoTech's return on equity.Company Net Margins Return on Equity Return on Assets SCYNEXIS-1,030.04% -53.47% -32.86% AIM ImmunoTech -12,594.21%-421.73%-147.54% Do analysts rate SCYX or AIM? AIM ImmunoTech has a consensus target price of $275.00, indicating a potential upside of 3,029.98%. Given AIM ImmunoTech's stronger consensus rating and higher possible upside, analysts plainly believe AIM ImmunoTech is more favorable than SCYNEXIS.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SCYNEXIS 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00AIM ImmunoTech 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders believe in SCYX or AIM? 54.4% of SCYNEXIS shares are held by institutional investors. Comparatively, 12.0% of AIM ImmunoTech shares are held by institutional investors. 4.9% of SCYNEXIS shares are held by company insiders. Comparatively, 0.0% of AIM ImmunoTech shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has stronger earnings and valuation, SCYX or AIM? SCYNEXIS has higher revenue and earnings than AIM ImmunoTech. SCYNEXIS is trading at a lower price-to-earnings ratio than AIM ImmunoTech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSCYNEXIS$3.75M7.91-$21.29M-$0.56-1.36AIM ImmunoTech$146K45.98-$28.96M-$24.00-0.37 SummarySCYNEXIS beats AIM ImmunoTech on 12 of the 16 factors compared between the two stocks. Get AIM ImmunoTech News Delivered to You Automatically Sign up to receive the latest news and ratings for AIM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AIM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AIM vs. The Competition Export to ExcelMetricAIM ImmunoTechBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$6.71M$276.92M$5.62B$20.84BDividend YieldN/AN/A4.25%3.65%P/E Ratio-18.69N/A28.5727.17Price / Sales45.98432.09423.3548.17Price / CashN/A22.4436.0222.28Price / Book43.939.478.134.56Net Income-$28.96M-$110.10M$3.24B$995.22M7 Day Performance-4.60%-0.96%0.16%-1.16%1 Month PerformanceN/A11.71%5.95%3.18%1 Year Performance-78.04%17.13%26.09%6.83% AIM ImmunoTech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AIMAIM ImmunoTech1.1114 of 5 stars$8.79-4.0%$275.00+3,030.0%-78.1%$6.71M$146K-18.6920Gap DownSCYXSCYNEXIS1.0638 of 5 stars$0.72+2.1%N/A-65.1%$27.94M$3.75M-1.2860Positive NewsENLVEnlivex Therapeutics2.8447 of 5 stars$1.15+2.7%$10.00+769.6%-12.8%$27.20MN/A-1.7470NRSNNeuroSense Therapeutics2.4602 of 5 stars$1.93+1.3%$14.00+627.3%+114.3%$26.38MN/A-3.5710COEPCoeptis Therapeutics0.396 of 5 stars$7.44+0.6%N/A+62.4%$26.10MN/A-1.282Gap DownTPSTTempest Therapeutics2.3404 of 5 stars$7.03+1.8%$30.00+327.0%-76.8%$25.85MN/A-0.3920Gap DownPASGPassage Bio2.5221 of 5 stars$0.40+6.3%$7.50+1,756.4%-67.7%$25.11MN/A-0.40130Stock SplitTENXTenax Therapeutics1.6682 of 5 stars$5.93+3.0%$17.50+195.4%+77.1%$24.59MN/A-2.399CARACara Therapeutics0.2178 of 5 starsN/AN/AN/A$24.33M$7.14M-0.2580Gap DownHigh Trading VolumeLSTALisata Therapeutics2.815 of 5 stars$2.82-1.6%$15.00+432.9%-25.6%$24.27M$1M-1.2230News CoveragePositive NewsAnalyst ForecastGap DownCVKDCadrenal Therapeutics2.9339 of 5 stars$12.16+4.2%$32.00+163.3%N/A$23.95MN/A-1.314 Related Companies and Tools Related Companies SCYX Alternatives ENLV Alternatives NRSN Alternatives COEP Alternatives TPST Alternatives PASG Alternatives TENX Alternatives CARA Alternatives LSTA Alternatives CVKD Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:AIM) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AIM ImmunoTech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AIM ImmunoTech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AIM Stock Alerts